Opens U.S. headquarters in Nashville – a leading healthcare and life sciences hub
Dxcover, a UK-based company improving early cancer detection with its AI-powered multiomic technology, announced the launch of its United States headquarters in Nashville, Tennessee. The move reflects Dxcover’s commitment to commercializing its PANAROMIC cancer test in the world’s biggest life sciences market.
Health Technology Insights: Encompass Health Plans 50-Bed Rehab Hospital in Las Vegas
“The launch of our U.S. headquarters in Nashville represents a major value-building milestone for Dxcover as we accelerate our mission to make early cancer detection accessible everywhere.” Matthew J. Baker, Ph.D., CEO and Co-founder of Dxcover
Dxcover’s innovative Drop. Dry. Detect. approach offers a cost-effective, high-throughput, non-invasive cancer screening platform. The new facilities will allow the company to forge partnerships with local biotech and healthcare organizations, advance local manufacturing of its innovative infrared spectroscopy platform and serve as a research and development hub aimed at extending Dxcover’s leadership in cancer diagnostics innovation.
Matthew J. Baker, Ph.D., CEO and Co-founder of Dxcover said: “The launch of our U.S. headquarters in Nashville represents a major value-building milestone for Dxcover as we accelerate our mission to make early cancer detection accessible everywhere.
Health Technology Insights: Aetna Supports Industry Actions to Simplify Prior Authorization
“Nashville is well known for its dynamic business environment in the healthcare field and we look forward to collaborating with research institutes, health organizations, and biotech start-ups to promote precision medicine and enhance early cancer detection solution access. Organizations such as Life Science Tennessee and BioTN are vital to the enhancement of life sciences innovation, and Dxcover is eager to be an active member of this growing collective.”
Dxcover’s PANAROMIC™ technology is transforming cancer screening through a multiomic approach through infrared spectroscopy and AI-driven spectral analysis. Unlike genetic-marker-based tests, Dxcover’s platform captures the complete biological signature from a tiny blood sample, enabling earlier diagnosis and better patient outcomes. The technology is scalable and already demonstrated proof-of-concept in various forms of cancer, including brain, colorectal, lung, and pancreatic cancers. Dxcover aims to bring high-tech diagnostics to underserved populations, enhancing global healthcare equity.
Health Technology Insights: GE Healthcare Drives Innovation In Theranostics With Latest Technological Advance
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
Source – businesswire
